This article has Open Peer Review reports available.
Comparative analysis of inflamed and non-inflamed colon biopsies reveals strong proteomic inflammation profile in patients with ulcerative colitis
© Poulsen et al.; licensee BioMed Central Ltd. 2012
Received: 16 February 2012
Accepted: 15 June 2012
Published: 24 June 2012
Accurate diagnostic and monitoring tools for ulcerative colitis (UC) are missing. Our aim was to describe the proteomic profile of UC and search for markers associated with disease exacerbation. Therefore, we aimed to characterize specific proteins associated with inflamed colon mucosa from patients with acute UC using mass spectrometry-based proteomic analysis.
Biopsies were sampled from rectum, sigmoid colon and left colonic flexure from twenty patients with active proctosigmoiditis and from four healthy controls for proteomics and histology. Proteomic profiles of whole colonic biopsies were characterized using 2D-gel electrophoresis, and peptide mass fingerprinting using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) was applied for identification of differently expressed protein spots.
A total of 597 spots were annotated by image analysis and 222 of these had a statistically different protein level between inflamed and non-inflamed tissue in the patient group. Principal component analysis clearly grouped non-inflamed samples separately from the inflamed samples indicating that the proteomic signature of colon mucosa with acute UC is strong. Totally, 43 individual protein spots were identified, including proteins involved in energy metabolism (triosephosphate isomerase, glycerol-3-phosphate-dehydrogenase, alpha enolase and L-lactate dehydrogenase B-chain) and in oxidative stress (superoxide dismutase, thioredoxins and selenium binding protein).
A distinct proteomic profile of inflamed tissue in UC patients was found. Specific proteins involved in energy metabolism and oxidative stress were identified as potential candidate markers for UC.
Ulcerative colitis (UC) is a chronic relapsing inflammatory disease of the colon. Together with Crohn´s disease (CD), UC is referred to as chronic inflammatory bowel diseases (IBD). In Denmark, the incidence of UC is approximately 10 per 100,000 . The underlying pathology of the disorder is complex and far from fully understood [2–7].
High throughput technologies like microarray and proteomic approaches can be utilized to identify disease markers, which can be used for diagnostic and monitoring purpose [8–12]. Based on these technologies several candidate markers being correlated with IBD disease phenotypes have been revealed, mainly identified from serum samples [13–17], but also from colon tissues [18–22]. Recently, biopsies from IBD patients were successfully examined in a multigene analysis resulting in diagnostic precision of IBD . Thus, seven marker genes were identified, where expression in colonic mucosal biopsies differed between patients with UC, patients with CD and patients with non-IBD. Moreover, by the use of these marker genes, the authors were able to distinguish between 38 patients with UC, 28 patients with CD and 20 patients with non-IBD in a prospective panel .
Fecal calprotectin is a very sensitive marker for intestinal inflammation, but it is not a specific marker and increased levels are also found in neoplasia, infections, polyps, and with use of non-steroidal anti-inflammatory drugs and increasing age . Thus, intestinal tissue samples are suggested to be the most important source for the identification of disease markers for further validation .
Markers may serve a wide range of purposes in IBD, such as diagnostic purposes, providing objective measures for disease activity, and as indicators for treatment outcome. Thus, a panel of markers is needed to cover these various clinical settings. For example the symptoms of IBD are often unspecific, and diagnosis may be delayed with devastating impact on disease progression as a result . Therefore, fast and reliable diagnostic tools are wanted .
During UC inflammation both the mucosa and submucosa will be affected, resulting in tissue damage and ulceration, and studies based on whole biopsies can thus be challenging due to tissue complexity. However, routine endoscopic evaluations enable easy examination of whole biopsies. With this in mind, proteomics is an ideal hypothesis-free approach to shed light on molecular characterization and diagnostics of intestinal inflammation .
The aim of this study was to apply a comparative proteomic approach in order to characterize the proteomic signature of inflamed versus non-inflamed colonic tissue from twenty UC patients in order to establish a baseline of markers, which are associated with active UC. This is the first study analysing the global proteomic signature of affected and non-affected colon tissues from more than a few UC patients using 2-dimensional gel electrophoresis (2-DGE) based proteomics coupled with mass spectrometry (MS). We found 222 protein spots which were significantly different expressed in inflamed versus non-inflamed tissue. Of these, 43 protein spots were identified and assigned to 33 individual proteins.
Patients and controls
Twenty patients (1:1 female–male ratio, mean age 40 (aged 18–67), 12 non-smokers, 7 former smokers and 1 current smoker) with proctosigmoiditis were recruited from Viborg Regional Hospital, Denmark. Diagnosis of proctosigmoiditis was based on clinical, endoscopic, and histological examinations . Of these, four patients were diagnosed with UC for the first time at the endoscopy. Among the 20 patients, ten were treated with 5-aminosalicylic acid, (5-ASA) one with salazopyrine, one with a diuretic and renin-angiotensin inhibitor due to arterial hypertension, and eight were without daily treatment. In addition, four voluntary healthy controls (1:1 female–male ratio, mean age 32 (aged 18–50)) without any familial disposition for inflammatory bowel disease, daily medication, or any known diseases were recruited by announcement. They were all without inflammation at the endoscopy.
Biopsies (3–10 mg) from patients and healthy controls were sampled by endoscopy conducted at the Medical Department at Viborg Regional Hospital, Denmark. All study subjects fasted 12 h prior to endoscopy. Samples were taken for both proteomics and histological analyses from each location. From the healthy controls replicate biopsies (two for proteomics, two for histology) were sampled from rectum (RE), sigmoid colon (SI) and left colonic flexure (LF), respectively, while, from patients, replicate biopsies (two for proteomics, two for histology) were sampled from acutely inflamed mucosa from RE (affected sample) or from non-inflamed mucosa from LF (control sample), respectively. Biopsy specimens were immediately stored in dry ice and subsequently stored at −80°C until preparation for 2-DGE.
The histological examination of inflamed, non-inflamed and normal tissue was conducted on specimens taken in the same area as those used for proteomic profiling and fully agreed with the clinical assessment. The excised biopsies were evaluated by a trained pathologist using hematoxylin and eosin staining. The pathologist was blinded for the clinical evaluation of the patients and the proteomic results. The specimens were evaluated by conventional histological criteria, including crypt distortion, goblet cell loss, inflammation in the mucosal lamina propria, subcryptal leukocyte infiltration and absence of changes specific for other diseases such as granulomas [28, 29]. Furthermore, the biopsies were graded using a simplified method for histological assessment of inflammation in UC , which includes crypt distortion (score 0–4), crypt inflammation (score 0–3) and subcryptal leukocyte infiltration (score 0–2) (maximum score was 7). Biopsy score from the healthy persons were 0 (25%-75% percentiles 0–0) for biopsies from left colonic flexure, sigmoid colon and rectum. Biopsy score from the patients were median 0 (25%-75% percentiles 0–1) from left colonic flexure and median 5 (25%-75% percentiles 4–5) from rectum.
Sample preparation and gel electrophoresis
Prior to 2-DGE whole mucosal biopsies were homogenized and lysed in buffer (1 mg biopsy/10 μl lysis buffer) consisting of 7 M urea, 2 M thiourea, 1.5% (wt/vol) pharmalyte (pH 3–10, GE Healthcare, Uppsala, Sweden), 0.8% (wt/vol) 3-[(3-chol-amidpropyl) dimethylammonium]-1-propansulfonate, CHAPS (Applichem, Darmstadt, Germany) and 1% (wt/vol) dithioerythritol in water. After 2 h incubation at room temperature, lysed cells were centrifuged for 20 min at 10,000 × g at 4°C, and the supernatant was aspirated. Total protein content was determined by BCA protein assay (BioRad), and 100 μg extracted protein from individual biopsies were subsequently separated using 2-DGE with proteins initially being separated in the first dimension according to isoelectric focusing using immobilized pH-gradient IPG strips (pH 5 to 8, 11 cm, BioRad, Hercules, CA). In order to achieve optimal focusing and gradient flow, the running conditions were 5 h at 200 V, 3 h at 500 V and 16 h at 3500 V. Hereafter, 12.5% sodium dodecyl sulphate polyacrylamide (SDS-PAGE) Criterion gels (BioRad) were used for second dimension separation with proteins running for 1 h at 200 V. For visualization of protein spots analytical gels were stained with Flamingo Pink (BioRad), and scanned at appropriate wavelength for fluorescence images (FX Pro Fluorescent Scanner, BioRad).
Gel images were processed and gel spots detected and quantified with Progenesis SameSpot (version 3.3, Nonlinear dynamics, Newcastle, UK). Initially a few anchor spots were manually defined and followed by the build-in automated alignment procedure. Spot border lines were created from a selected reference gel and applied to all gels. After background subtraction, a gel to gel normalization based on a logarithmic abundance ratio of the spot volumes was performed in order to minimize bias from e.g. pipetting errors, when loading sample, or inconsistency in the transfer of proteins from the first to the second dimension. The output dataset contained no missing values since all spot areas were present, and quantified in all gels. The resulting normalized spot volumes were subsequently analyzed in order to identify spots with different protein expression between groups.
In-gel digestion and peptide mass fingerprinting
For peptide mass fingerprinting (PMF) proteins of interest were subjected to in-gel digestion by addition of trypsin using an in-gel protocol, essentially as described by Jensen et al. . Custom-made chromatographic columns were used for desalting and concentration of the peptide mixture prior to MS analysis . Hereafter, peptides were eluted in 0.5 μL of matrix solution (15–20 g/L of α-cyano-4-hydroxycinnamic acid; Sigma Aldrich, St. Louis, USA, in 70% acetonitrile) directly onto the MALDI target plate (Bruker Daltonics GmbH, Bremen, Germany). Mass spectra were obtained using an Ultraflex MALDI-TOF tandem mass spectrometer in reflection mode (Bruker Daltonics, Bremen, Germany). A peptide calibration standard ranging from 1046.54 to 3147.47 g/mol was spotted separately onto the MALDI target plate. The ion-accelerating voltage was 25 kV and the laser frequency of 50 Hz with 200 laser spots accumulated for each spectrum. For tandem mass spectrometry (MS/MS, lift mode), the ion accelerating voltage was 19 kV, and the protein was identified based on the Mascot scores of the peptide subjected to MS/MS analysis.
In order to identify spots with significantly different protein levels in the inflamed versus non-flamed mucosa of UC patients, we applied a one-way analysis of variance (t-test) using the logarithm of the normalized spot volumes. A false discovery rate (FDR), the proportion of significant features that turn out to be false due to multiple testing was calculated as q-value . We also applied multivariate statistics, which is ideal for 2-DGE datasets typically consisting of long and lean data with relatively few observations (samples) and many variables (protein spots). The normalized spot volumes were imported into SIMCA 9.0 (Umetrics), and preprocessed with mean centering. For principal component analysis (PCA) of proteomic data from control persons, data was autoscaled, while group scaling was considered to be a more optimal scaling approach for PCA of proteomic data from patients. While autoscaling is based on overall standard deviation, group scaling is based upon the within-group standard deviation, and therefore gives a higher weight to the group-dependent proteins .
PMF mass searches were conducted in the Mascot ions search engine (Matrix Science, Boston, USA) using the Swiss-Prot database (Swiss Institute of Bioinformatics, Geneva, Switzerland). The Mascot software uses a scoring algorithm to identify the closest match and significant protein identification. The ions score is −10*Log(P), where P is the probability, that the observed match is a random event. In this study a protein score having a significance level of P < 0.05 indicated identity or extensive homology. For MS/MS identification, fragmentation of the parent ion was followed by mass searches in the database.
All subjects received written and oral information and gave written informed consent. The study was done in accordance with the Declaration of Helsinki and was approved by the Danish Regional Ethics Committee (VN 20060041).
Proteomic profiles of control persons and UC patients
The protein composition of biopsies from UC patients differed in the non-inflamed versus inflamed mucosa. After manual gel inspection of spot alignment, the image analysis annotated a total of 597 spots. Statistical significance (P < 0.05) was achieved for 222 spots being differentially expressed in inflamed versus non-inflamed mucosa, and of these 39 spots were highly significant (P < 0.0001). After correction for multiple testing by FDR, the proportion of significant spots estimated to be false positives were 4.1% for a statistical significance level of 0.05 (q = 0.041) and 0.05% for a statistical significance level of 0.0001 (q = 0.0005).
List of significant proteins showing more than twofold altered protein expression within UC patients
SwissProt Acc. no.
S cov %1
T -test (p)4
Higher level in RE
B-cell antigen receptor complex-associated protein beta chain
Plasma-cell induced resident endoplasmatic reticulum protein
L-lactate dehydrogenase B-chain
Tubulin beta 5-chain
Lower level in RE
Selenium binding protein
Carbonic anhydrase 2
Selenium binding protein
List of additional significant proteins identified in UC patients
S cov %1
T -test (p)4
Higher level in RE
F-actin capping protein subunit alpha-1
F-actin capping protein subunit beta
Lower level in RE
Selenium binding protein
Elongation factor Tu
Tubulin alpha-6 chain
Carbonic anhydrase 1
Thioredoxin-dependent peroxide reductase
Heat shock protein 70 kDa /Serum albumin
60 kDa heat shock protein
Changes in proteomic signatures in control persons versus UC patients
In order to assess whether spots showing different protein level within UC patients could be supported by information from the control persons, the identified spots were examined in RE and LF from both control persons and UC patients. In this way, protein spots that merely reflected position effects (i.e. showing the same difference in the control group) or nonsense patterns (e.g. when the control group resemble patient RE) rather than distinct inflammation profiles could be evaluated. Using this approach five of the identified spots (alpha-enolase (spot 10 and spot 43), hydroxymethylglutaryl–CoA synthase, cathepsin D and 60 kDa heat shock protein) did not qualify for candidate marker. Alpha-enolase (spot 10) and hydroxymethylglutaryl–CoA synthase both had a significantly different protein level in the control biopsies as well as in the patient biopsies when comparing RE and LF, and showed a similar pattern in both groups that could indicate that these proteins were rather position markers than disease markers. Regarding alpha-enolase (spot 43), cathepsin D and 60 kDa heat shock protein, the protein levels in the inflamed mucosa (RE) were similar to RE and LF level from control persons.
Candidate markers and affected biological pathways
Biological processes associated with identified proteins with references to results obtained in earlier studies
triosephosphate isomerase1,3,4, glycerol-3-phosphate-dehydrogenase, alpha enolase2,3, isocitrate dehydrogenase, L-lactate dehydrogenase B-chain, inorganic pyrophosphatase, enoyl-CoA hydratase
Response to oxidative stress
selenium binding protein1,2, superoxide dismutase, thioredoxin-dependent peroxide reductase1, peroxiredoxin-14, peroxiredoxin-4, peroxiredoxin-6
Stress response proteins
Alpha-enolase3, Hsp601,3, Hsp701,4
In this study samples from both inflamed and non-inflamed tissues from each patient were analyzed. The histological assessment of the biopsies confirmed that the patient biopsy from the left colonic flexure could be assessed as non-inflamed and did not show any signs of sub-inflammation. This is the first study to assess a relatively high number of UC patients using this approach and in spite of large individual heterogeneity we found statistical support for tissue specific levels of many proteins being associated with disease exacerbation. Recently, proteomic studies have contributed with promising candidate markers being correlated with disease phenotypes, either in IBD patients in general, specifically within UC patients or between UC, CD and control persons [20–22].
In this study, the spots characterized by a larger than twofold difference in protein level were classified as the most promising markers. These spots together with the additional spots identified included proteins already known to be associated with inflammation states of IBD (e.g. triosephosphate isomerase, alpha enolase, selenium binding protein, superoxide dismutase, thioredoxin-dependent peroxide reductase, Hsp60, Hsp70) [19, 22, 34], as well as novel proteins (e.g. glycerol-3-phosphate-dehydrogenase, isocitrate dehydrogenase, L-lactate dehydrogenase B-chain, inorganic pyrophosphatase, enoyl-CoA hydratase, peroxiredoxin-4, peroxiredoxin-6), where the association with UC and inflammation needs replication. Integration of excised biopsies from control persons was used to strengthen our conclusions, since protein spots showing different protein levels between RE and LF colon mucosa of control persons could be excluded as merely position specific markers, and not disease markers. Furthermore, there is a strong support for regarding our significant spots as true positives since only nine false positives are expected out of 222 spots (q = 0.041), and only 0.02 spot out of the 39 highly significant (q = 0.0005).
The proteomic profile of the inflamed tissue was very distinct with 37% of the annotated protein spots having significantly different protein levels when comparing inflamed and non-inflamed patient mucosa. Focusing on the spots found to have at least more than twofold difference in protein level between patient biopsies, 70% (14 spots out of 20 possible) were successfully identified. Further identification of additional protein spots with strong statistical support strengthened the overall understanding of how inflammation changes the proteomic signature of UC patient colon biopsies. We found that, apart from the highly abundant proteins like serum albumin and cytoplasmic actin, excised spots could primarily be assigned to proteins involved in stress response mechanisms and energy metabolism. Different levels of these proteins could infer that acute inflammation in UC patients in particular impair and affect regulation of these biological processes.
Different protein profiles of several glycolytic enzymes (triosephosphate isomerase, glycerol-3-phosphate-dehydrogenase, alpha enolase) and other proteins involved in energy generation (isocitrate dehydrogenase, L-lactate dehydrogenase B-chain, inorganic pyrophosphatase, enoyl-CoA hydratase) could indicate inflammation associated alterations in energy metabolism in UC patients. This could be due to malfunction of the utilization of n-butyrate, which is the preferred fuel for colonocytes in the distal colon . The observed lowered enoyl-CoA hydratase in inflamed tissue infer impaired fatty acid oxidation and the energy-deficiency is further strengthened by change in the glycolytic pathway reflected as a higher expression of glycolytic enzymes in inflamed mucosa. In accordance with the present findings, Hsieh et al.  observed a down-regulation of triosephosphate isomerase in UC-diseased colon mucosa, while Nanni et al.  observed an up-regulation of the same enzyme in intestinal epithelial cells from CD patients. In addition, a changed regulation of alpha-enolase has been associated with IBD , which has been suggested to reflect anaerobic glycolysis in UC patients with inflamed pouch . However, changes in the level of alpha-enolase could also reflect non-glycolytic mechanisms, since the protein is also induced as a heat shock protein under hypoxic stress . Induced expression of heat shock proteins due to cellular stress would probably be expected in IBD patients [39–41] and is further reflected in the lower expression of 60 and 70 kDa heat shock proteins observed in inflamed tissue.
Inflammation in IBD patients generally increases the level of reactive oxygen metabolites resulting in oxidative stress due to an imbalance between antioxidants and reactive oxygen [42, 43]. Different levels of several antioxidant proteins (selenium binding protein, superoxide dismutase, thioredoxin-dependent peroxide reductase, peroxiredoxin-4 and peroxiredoxin-6) suggest an increased level of oxidative stress in UC patients, and earlier studies have specifically documented a regulation of selenium-binding protein and superperoxide dismutase in relation to patients with IBD [26, 44–46]. Impaired oxidative metabolism and affected antioxidant defenses thus seem to play an important role in the pathogenesis of IBD diseases, and changed expression of involved protein is most likely related to a stimulated cell activity (e.g. neutrophils) due to severe inflammation.
Generally, the control persons demonstrated a high variability among individuals reflecting an individual protein signature rather than a strong position specific proteomic profile of biopsies excised from the same bowel location in different individuals. However, some proteins were still found to be significantly differently expressed between RE and LF tissues, indicating that these could be assigned as position markers. Two of the spots found to represent very different protein levels within the UC patients fell into this category (α-enolase (spot 10) and hydroxymethyl glutaryl-CoA synthase). These proteins could falsely have been ascribed as good candidates for disease markers if the control persons were not taken into account. Regardless of the need for control persons in terms of validation of markers as actual disease markers, and not just position markers, internal controls within the same patient seems to be a robust and more simplistic approach to implement. Here, the control persons were healthy, while in other studies, controls have been patients with e.g. colorectal carcinoma [19, 45], which could complicate the interpretation of results, since UC and colorectal carcinoma are closely linked conditions, and even tumor free tissue from cancer patients could deviate from normal tissue . We have not addressed the individual variation in protein level between patients, which could be substantial , but instead focused on protein spots having robust signatures across patients.
Overall, 2-DGE analysis has improved in relation to reproducibility, repeatability and better image analysis, and in this study the limitation related to PMF using MALDI-TOF MS technology, was due to the quantity of the protein spots and sensitivity of the instrument, which played a major role for successful protein identification. Despite its flaws, MS-based proteomic techniques are efficient in providing new insights into pathogenesis of diseases not only through identification of involved proteins but also for potential effects of different isoforms, like post-translational modifications . We observed several individual proteins being assigned to multiple spots (e.g. alpha-enolase), but the underlying modifications were not studied further. Some proteins with horizontal patterns could for instance, indicate phosphorylations, changing the charge of proteins as observed in the train of protein spots assigned to selenium binding protein.
Protein extraction from whole colonic biopsies as conducted here means that a long and tedious procedure for isolation of e.g. intestinal epithelial cells is avoided. On the other hand the proteomic profile from diverse cell types of both intestinal and immune origin could potentially result in larger variability between the samples and a limited control of cell specific signatures, with a risk of some cell types overruling important expression patterns of others . Essentially, whole biopsies from IBD patients contain multiple populations of cells, including inflammatory cells, and thereby proteins identified could potentially reflect other mechanisms resulting from i.e. cell death or serum. To avoid introduction of sources of errors whole biopsies is preferred for clinical use. Our study thus resembles the clinical setting in this respect. Precautions in relation to collection, processing and storage should be taken seriously for minimizing factors that potentially could alter the molecular composition of the tissue material . Here, the biopsies were stored immediately on dry ice after collection and subsequently on −80°C, which in combination with gentle handlings throughout all analyses ensure a high quality of the collected material.
The patients in the UC cohort included in this study received different medical treatments, which potential could affect their protein profiles. Based on the PCA plot, the variation among the patient group treated with 5-ASA was, however, not different from the remaining patients, and therefore it was not evident that the treatment had a strong effect on the proteomic signature of the analyzed biopsies.
In conclusion, we have generated insights into the underlying mechanisms of active UC. The overall proteomic signature of inflamed colon mucosa was strong. Such assessment of biopsies from the active site of the disease reveal protein markers associated with inflamed tissue, and could be an important entry point for the discovery of new and improved non-invasive markers . Thus, future studies further addressing the marker proteins found are essential for evaluation of disease specificity and clinical relevance.
Patients and healthy controls are thanked for their participation. We thank the staff at the Library and Information Department, Viborg Regional Hospital, Denmark for valuable assistance. We thank consultant Lars Vinter-Jensen for assistance with endoscopy of the healthy controls. We thank the Danish Colitis Crohn’s Foundation.
- Jacobsen BA, Fallingborg J, Rasmussen HH, Nielsen KR, Drewes AM, Puho E, Nielsen GL, Sorensen HT: Increase in incidence and prevalence of inflammatory bowel disease in northern Denmark: a population-based study, 1978–2002. Eur J Gastroenterol Hepatol. 2006, 18: 601-606. 10.1097/00042737-200606000-00005.View ArticlePubMedGoogle Scholar
- Thompson AI, Lees CW: Genetics of ulcerative colitis. Inflamm Bowel Dis. 2011, 17: 831-848. 10.1002/ibd.21375.View ArticlePubMedGoogle Scholar
- Anderson CA, Boucher G, Lees CW, Franke A, D'Amato M, Taylor KD, Lee JC, Goyette P, Imielinski M, Latiano A, Lagace C, Scott R, Amininejad L, Bumpstead S, Baidoo L, Baldassano RN, Barclay M, Bayless TM, Brand S, Buning C, Colombel JF, Denson LA, De Vos M, Dubinsky M, Edwards C, Ellinghaus D, Fehrmann RSN, Floyd JAB, Florin T, Franchimont D, et al: Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47. Nat Genet. 2011, 43: 246-252. 10.1038/ng.764.View ArticlePubMedPubMed CentralGoogle Scholar
- Andersen V, Ernst A, Christensen J, Ostergaard M, Jacobsen B, Tjonneland A, Krarup H, Vogel U: The polymorphism rs3024505 proximal to IL-10 is associated with risk of ulcerative colitis and Crohns disease in a Danish case–control study. BMC Med Genet. 2010, 11: 82-View ArticlePubMedPubMed CentralGoogle Scholar
- Andersen V, Nimmo E, Krarup HB, Drummond H, Christensen J, Ho GT, Ostergaard M, Ernst A, Lees C, Jacobsen BA, Satsangi J, Vogel U: Cyclooxygenase-2 (COX-2) Polymorphisms and Risk of Inflammatory Bowel Disease in a Scottish and Danish Case–control Study. Inflamm Bowel Dis. 2011, 17: 937-946. 10.1002/ibd.21440.View ArticlePubMedGoogle Scholar
- Andersen V, Christensen J, Ernst A, Jacobsen BA, Tjonneland A, Krarup HB, Vogel U: Polymorphisms in NF-kappa B, PXR, LXR, PPAR gamma and risk of inflammatory bowel disease. World J Gastroenterol. 2011, 17: 197-206. 10.3748/wjg.v17.i2.197.View ArticlePubMedPubMed CentralGoogle Scholar
- Baumgart DC, Carding SR: Inflammatory bowel disease: cause and immunobiology. Lancet. 2007, 369: 1627-1640. 10.1016/S0140-6736(07)60750-8.View ArticlePubMedGoogle Scholar
- Alex P, Gucek M, Li XH: Applications of proteomics in the study of inflammatory bowel diseases: Current status and future directions with available technologies. Inflamm Bowel Dis. 2009, 15: 616-629. 10.1002/ibd.20652.View ArticlePubMedPubMed CentralGoogle Scholar
- Werner T, Haller D: Intestinal epithelial cell signalling and chronic inflammation: From the proteome to specific molecular mechanisms. Mutat Res. 2007, 622: 42-57. 10.1016/j.mrfmmm.2007.05.010.View ArticlePubMedGoogle Scholar
- Kok K, Stokkers P, Reitsma PH: Genomics and proteomics - Implications for inflammatory bowel diseases. Inflamm Bowel Dis. 2004, 10: S1-S6. 10.1097/00054725-200401000-00001.View ArticlePubMedGoogle Scholar
- Roda G, Caponi A, Benevento M, Nanni P, Mezzanotte L, Belluzzi A, Mayer L, Roda A: New proteomic approaches for biomarker discovery in inflammatory bowel disease. Inflamm Bowel Dis. 2010, 16: 1239-1246.View ArticlePubMedGoogle Scholar
- Din S, Lennon AM, Arnott ID, Hupp T, Satsangi J: Technology insight: the application of proteomics in gastrointestinal disease. Nat Clin Pract Gastroenterol Hepatol. 2007, 4: 372-385. 10.1038/ncpgasthep0872.View ArticlePubMedGoogle Scholar
- Nanni P, Parisi D, Roda G, Casale M, Belluzzi A, Roda E, Mayer L, Roda A: Serum protein profiling in patients with inflammatory bowel diseases using selective solid-phase bulk extraction, matrix-assisted laser desorption/ionization time-of-flight mass spectrometry and chemometric data analysis. Rapid Commun Mass Spectrom. 2007, 21: 4142-4148. 10.1002/rcm.3323.View ArticlePubMedGoogle Scholar
- Meuwis MA, Fillet M, Chapelle JP, Malaise M, Louis E, Merville MP: New biomarkers of Crohn´s disease: serum biomarkers and development of diagnostic tools. Expert Rev Mol Diagn. 2008, 8: 327-337. 10.1586/1473718.104.22.1687.View ArticlePubMedGoogle Scholar
- Meuwis MA, Fillet M, Geurts P, de Seny D, Lutteri L, Chapelle JP, Bours V, Wehenkel L, Belaiche J, Malaise M, Louis E, Merville MP: Biomarker discovery for inflammatory bowel disease, using proteomic serum profiling. Biochem Pharmacol. 2007, 73: 1422-1433. 10.1016/j.bcp.2006.12.019.View ArticlePubMedGoogle Scholar
- Li XH, Conklin L, Alex P: New serological biomarkers of inflammatory bowel disease. World J Gastroenterol. 2008, 14: 5115-5124. 10.3748/wjg.14.5115.View ArticlePubMedPubMed CentralGoogle Scholar
- Kanmura S, Uto H, Numata M, Hashimoto S, Moriuchi A, Fujita H, Oketani M, Ido A, Kodama M, Ohi H, Tsubouchi H: Human Neutrophil peptides 1–3 are useful biomarkers in patients with active ulcerative colitis. Inflamm Bowel Dis. 2009, 15: 909-917.View ArticlePubMedGoogle Scholar
- Von Stein P, Lofberg R, Kuznetsov NV, Gielen AW, Persson JO, Sundberg R, Hellstrom K, Eriksson A, Befrits R, Ost A, Von Stein OD: Multigene analysis can discriminate between ulcerative colitis, Crohn's disease, and irritable bowel syndrome. Gastroenterology. 2008, 134: 1869-1881. 10.1053/j.gastro.2008.02.083.View ArticlePubMedGoogle Scholar
- Shkoda A, Werner T, Daniel H, Gunckel M, Rogler G, Haller D: Differential protein expression profile in the intestinal epithelium from patients with inflammatory bowel disease. J Proteome Res. 2007, 6: 1114-1125. 10.1021/pr060433m.View ArticlePubMedGoogle Scholar
- Comelli EM, Lariani S, Zwahlen MC, Fotopoulos G, Holzwarth JA, Cherbut C, Dorta G, Corthesy-Theulaz I, Grigorov M: Biomarkers of human gastrointestinal tract regions. Mamm Genome. 2009, 20: 516-527. 10.1007/s00335-009-9212-7.View ArticlePubMedGoogle Scholar
- Wu F, Dassopoulos T, Cope L, Maitra A, Brant SR, Harris ML, Bayless TM, Parmigiani G, Chakravarti S: Genome-wide gene expression differences in Crohn's disease and ulcerative colitis from endoscopic pinch biopsies: Insights into distinctive pathogenesis. Inflamm Bowel Dis. 2007, 13: 807-821. 10.1002/ibd.20110.View ArticlePubMedGoogle Scholar
- Hsieh SY, Shih TC, Yeh CY, Lin CJ, Chou YY, Lee YS: Comparative proteomic studies on the pathogenesis of human ulcerative colitis. Proteomics. 2006, 6: 5322-5331. 10.1002/pmic.200500541.View ArticlePubMedGoogle Scholar
- Mendoza JL, Abreu MT: Biological markers in inflammatory bowel disease: Practical consideration for clinicians. Gastroenterol Clin Biol. 2009, 33: S158-S173.View ArticlePubMedGoogle Scholar
- Lopes LV, Kussmann M: Proteomics at the interface of phychology, gut physiology and dysfunction: an underexploited approach that deserves expansion. Expert Rev Proteomics. 2011, 8: 605-614. 10.1586/epr.11.50.View ArticlePubMedGoogle Scholar
- Vatn M: Natural history and complications of IBD. Curr Gastroenterol Rep. 2009, 11: 481-487. 10.1007/s11894-009-0073-8.View ArticlePubMedGoogle Scholar
- Lewis JD: The Utility of Biomarkers in the Diagnosis and Therapy of Inflammatory Bowel Disease. Gastroenterology. 2011, 140: 1817-1826. 10.1053/j.gastro.2010.11.058.View ArticlePubMedPubMed CentralGoogle Scholar
- Podolsky DK: Inflammatory Bowel Disease. N Engl J Med. 2002, 347: 417-429. 10.1056/NEJMra020831.View ArticlePubMedGoogle Scholar
- Geboes K, Riddell R, Öst A, Jensfelt B, Persson T, Löfberg R: A reproducible grading scale for histological assessment of inflammation in ulcerative colitis. Gut. 2000, 47: 404-409. 10.1136/gut.47.3.404.View ArticlePubMedPubMed CentralGoogle Scholar
- Day DW, Jass JR, Price AB, Shepherd NA, Sloan JM, Talbot IC, Warren BF, Williams GT: Inflammatory disorders of the large intestine. 2003, Morson and Dawson's Gastrointestinal Pathology. Blackwell Science Ltd, In, 472-539.Google Scholar
- Jensen ON, Larsen MR, Roepstorff P: Mass spectrometric identification and microcharacterization of proteins from electrophoretic gels: Strategies and applications. Proteins. 1998, 2: 74-89.View ArticlePubMedGoogle Scholar
- Lametsch R, Roepstorff P, Bendixen E: Identification of protein degradation during post-mortem storage of pig meat. J Agric Food Chem. 2002, 50: 5508-5512. 10.1021/jf025555n.View ArticlePubMedGoogle Scholar
- Storey JD: A direct approach to false discovery rates. J R Stat Soc B. 2002, 64: 479-498. 10.1111/1467-9868.00346.View ArticleGoogle Scholar
- Jensen KN, Jessen F, Jorgensen BM: Multivariate data analysis of two-dimensional gel electrophoresis protein patterns from few samples. J Proteome Res. 2008, 7: 1288-1296. 10.1021/pr700800s.View ArticlePubMedGoogle Scholar
- Turroni S, Vitali B, Candela M, Gionchetti P, Rizzello F, Campieri M, Brigidi P: Antibiotics and probiotics in chronic pouchitis: A comparative proteomic approach. World J Gastroenterol. 2010, 16: 30-41.PubMedPubMed CentralGoogle Scholar
- Nanni P, Mezzanotte L, Roda G, Caponi A, Levander F, James P, Roda A: Differential proteomic analysis of HT29 Cl.16E and intestinal epithelial cells by LC ESI/QTOF mass spectrometry. J Proteomics. 2009, 72: 865-873. 10.1016/j.jprot.2008.12.010.View ArticlePubMedGoogle Scholar
- Roediger WEW: The colonic epithelium in Ulcerative-Colitis - An Energy-Deficiency Disease. Lancet. 1980, 2: 712-715.View ArticlePubMedGoogle Scholar
- Vermeulen N, Arijs I, Joossens S, Vermeire S, Clerens S, Van den Bergh K, Michiels G, Arckens L, Schuit F, Van Lommel L, Rutgeerts P, Bossuyt X: Anti-alpha-enolase antibodies in patients with inflammatory bowel disease. Clin Chem. 2008, 54: 534-541. 10.1373/clinchem.2007.098368.View ArticlePubMedGoogle Scholar
- Aaronson RM, Graven KK, Tucci M, McDonald RJ, Farber HW: Non-neuronal enolase is an endothelial hypoxic stress protein. J Biol Chem. 1995, 270: 27752-27757. 10.1074/jbc.270.46.27752.View ArticlePubMedGoogle Scholar
- Ludwig D, Stahl M, Ibrahim ME, Wenzel BE, Drabicki D, Wecke A, Fellermann K, Stange EF: Enhanced intestinal expression of heat shock protein 70 in patients with inflammatory bowel diseases. Dig Dis Sci. 1999, 44: 1440-1447. 10.1023/A:1026616221950.View ArticlePubMedGoogle Scholar
- Winrow VR, Mojdehi GM, Ryder SD, Rhodes JM, Blake DR, Rampton DS: Stress Proteins in Colorectal Mucosa - Enhanced Expression in Ulcerative-Colitis. Dig Dis Sci. 1993, 38: 1994-2000. 10.1007/BF01297075.View ArticlePubMedGoogle Scholar
- Araki K, Mikami T, Yoshida T, Kikuchi M, Sato Y, Oh-ishi M, Kodera Y, Maeda T, Okayasu I: High expression of HSP47 in ulcerative colitis-associated carcinomas: proteomic approach. Br J Cancer. 2009, 101: 492-497. 10.1038/sj.bjc.6605163.View ArticlePubMedPubMed CentralGoogle Scholar
- Kruidenier L, Verspaget HW: Review article: oxidative stress as a pathogenic factor in inflammatory bowel disease - radicals or ridiculous?. Aliment Pharmacol Ther. 2002, 16: 1997-2015. 10.1046/j.1365-2036.2002.01378.x.View ArticlePubMedGoogle Scholar
- Kruidenier L, Kuiper I, van Duijn W, Mieremet-Ooms MAC, van Hogezand RA, Lamers CBHW, Verspaget HW: Imbalanced secondary mucosal antioxidant response in inflammatory bowel disease. J Pathol. 2003, 201: 17-27. 10.1002/path.1408.View ArticlePubMedGoogle Scholar
- LihBrody L, Powell SR, Collier KP, Reddy GM, Cerchia R, Kahn E, Weissman GS, Katz S, Floyd RA, McKinley MJ, Fisher SE, Mullin GE: Increased oxidative stress and decreased antioxidant defenses in mucosa of inflammatory bowel disease. Dig Dis Sci. 1996, 41: 2078-2086. 10.1007/BF02093613.View ArticleGoogle Scholar
- Kruidenier L, Kuiper I, van Duijn W, Marklund SL, van Hogezand RA, Lamers CBHW, Verspaget HW: Differential mucosal expression of three superoxide dismutase isoforms in inflammatory bowel disease. J Pathol. 2003, 201: 7-16. 10.1002/path.1407.View ArticlePubMedGoogle Scholar
- Dagli U, Balk M, Yucel D, Ulker A, Over H, Saydam G, Sahin B: The role of reactive oxygen metabolites in ulcerative colitis. Inflamm Bowel Dis. 1997, 3: 260-264. 10.1002/ibd.3780030404.PubMedGoogle Scholar
- Polley ACJ, Mulholland F, Pin C, Williams EA, Bradburn DM, Mills SJ, Mathers JC, Johnson IT: Proteomic analysis reveals field-wide changes in protein expression in the morphologically normal mucosa of patients with colorectal neoplasia. Cancer Res. 2006, 66: 6553-6562. 10.1158/0008-5472.CAN-06-0534.View ArticlePubMedGoogle Scholar
- Mann M, Jensen ON: Proteomic analysis of post-translational modifications. Nat Biotechnol. 2003, 21: 255-261. 10.1038/nbt0303-255.View ArticlePubMedGoogle Scholar
- Moore HM, Kelly AB, Jewell SD, McShane LM, Clark DP, Greenspan R, Hayes DF, Hainaut P, Kim P, Mansfield E, Potapova O, Riegman P, Rubenstein Y, Seijo E, Somiari Sm, Watson P, Weier H, Zhu C, Vaught J: Biospecimen reporting for improved study quality (BRISQ). J Proteome Res. 2011, 10: 3429-3438. 10.1021/pr200021n.View ArticlePubMedPubMed CentralGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-230X/12/76/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.